AzurRx BioPharma, Inc.
Company Snapshot: AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections.
- Aug 13 2019 AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Jul 22 2019 AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock
- Jul 17 2019 AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock
- Jul 17 2019 AzurRx BioPharma Announces Proposed Public Offering of Common Stock